MOTS-c is scientifically distinctive - a peptide encoded inside mitochondrial DNA that acts like a metabolic signal - and it earned a spot in the FDA's July 2026 compounding review, which sent search interest vertical. The science is early but real; the marketing runs years ahead of it.
What MOTS-c is
MOTS-c ('mitochondrial open reading frame of the twelve S rRNA type-c') is a 16-amino-acid peptide encoded within mitochondrial DNA. In published research it translocates to the nucleus under metabolic stress and regulates genes tied to glucose handling and cellular energy - behaving like an exercise-responsive hormone. Levels decline with age, feeding the longevity narrative.
The evidence base
- Animal data: improved insulin sensitivity, exercise capacity, and resistance to diet-induced obesity in mice - the studies behind the 'exercise in a vial' framing.
- Human data: observational studies linking MOTS-c levels to metabolic health, plus very small early-phase work. No adequately powered human efficacy trial for any indication as of August 2026.
- Regulatory: reviewed by the FDA's Pharmacy Compounding Advisory Committee in July 2026 alongside BPC-157 and others. Committee recommendations are consultative - no reclassification has been enacted, and no legal compounding pathway exists today.
The dosage math
Gray-market MOTS-c is denominated in milligrams (typical vials 5-10 mg). A 10 mg vial with 2 ml of bacteriostatic water is 5 mg/ml; a 5 mg amount would be a full 1 ml - 100 units, the entire capacity of the largest insulin syringe, which is exactly the kind of practical constraint the calculator flags before you're holding a syringe wondering why it doesn't fit.
The gray-market protocol lore, quantified
| Lore protocol | Vial math (10 mg + 2 ml) | Reality check |
|---|---|---|
| 5 mg twice weekly | 1 ml = 100 units, a full large syringe per dose | Physically awkward; the flag our calculator raises |
| 10 mg once weekly | Entire vial per dose | One vial per week at research-chemical prices |
| 2.5 mg three times weekly | 0.5 ml = 50 units | The most syringe-practical of the circulating patterns |
None of these patterns comes from a trial: they are forum conventions quantified here so the arithmetic, at least, is right. The calculator handles your actual numbers.
Safety unknowns
Short human exposures in early studies did not surface acute safety signals, but there is no long-term human dataset for exogenous MOTS-c by any route. As a metabolic signaling peptide, the theoretical questions (insulin signaling interactions, chronic AMPK activation) are unstudied in humans. Research-vial purity adds the usual layer of practical risk.
Frequently asked questions
Did the FDA ban or approve MOTS-c in 2026?
Neither. The July 2026 PCAC meeting reviewed it for potential compounding eligibility; recommendations are consultative and no status change has been enacted. It remains an unapproved compound with no legal compounding pathway as of August 2026.
What is MOTS-c used for?
In research: metabolic regulation, insulin sensitivity, and exercise-capacity models, almost entirely in animals. Marketed uses (fat loss, endurance, longevity) have not been demonstrated in controlled human trials.
What's a typical MOTS-c dosage?
No human dose is evidence-established. Gray-market discussion clusters around 5-10 mg once or twice weekly - extrapolation, not data. The calculator converts whatever amount a clinician specifies into syringe units.